Cargando…

A First-Generation Pediatric Cancer Dependency Map

Exciting therapeutic targets are emerging from CRISPR-based screens of high mutational burden adult cancers. A key question, however, is whether functional genomic approaches will yield new targets in pediatric cancers, known for remarkably few mutations which often encode proteins considered challe...

Descripción completa

Detalles Bibliográficos
Autores principales: Dharia, Neekesh V., Kugener, Guillaume, Guenther, Lillian M., Malone, Clare F., Durbin, Adam D., Hong, Andrew L., Howard, Thomas P., Bandopadhayay, Pratiti, Wechsler, Caroline S., Fung, Iris, Warren, Allison C., Dempster, Joshua M., Krill-Burger, John M., Paolella, Brenton R., Moh, Phoebe, Jha, Nishant, Tang, Andrew, Montgomery, Philip, Boehm, Jesse S., Hahn, William C., Roberts, Charles W. M., McFarland, James M., Tsherniak, Aviad, Golub, Todd R., Vazquez, Francisca, Stegmaier, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049517/
https://www.ncbi.nlm.nih.gov/pubmed/33753930
http://dx.doi.org/10.1038/s41588-021-00819-w
Descripción
Sumario:Exciting therapeutic targets are emerging from CRISPR-based screens of high mutational burden adult cancers. A key question, however, is whether functional genomic approaches will yield new targets in pediatric cancers, known for remarkably few mutations which often encode proteins considered challenging drug targets. To address this, we created a first-generation Pediatric Cancer Dependency Map representing 13 pediatric solid and brain tumor types. Eighty-two pediatric cancer cell lines were subjected to genome-scale CRISPR-Cas9 loss-of-function screening to identify genes required for cell survival. In contrast to the finding that pediatric cancers harbor fewer somatic mutations, we found a similar complexity of genetic dependencies in pediatric cancer cell lines compared to adult models. Findings from the Pediatric Cancer Dependency Map provide pre-clinical support for ongoing precision medicine clinical trials. The vulnerabilities seen in pediatric cancers were often distinct from adult, indicating that repurposing adult oncology drugs will be insufficient to address childhood cancers.